Sponsor: Incyte Corp.
Sponsor Study ID: INCB 18424-269 / AALL1521
Study Title: A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia
CTO #: 102644
NCT Number: NCT02723994
Phase: II
Protocol Type: Treatment
Age Group: Children
Disease Sites: Lymphoid Leukemia
Study Objectives: This is a nonrandomized study of ruxolitinib in combination with a standard multi-agent chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (ruxolitinib) in combination with the chemotherapy regimen. Part 2 will evaluate the efficacy of combination chemotherapy and ruxolitinib at the recommended dose determined in Part 1.